« Return to News | Clinical Intelligence

Sangamo BioSciences to present results

Friday, March 11, 2011 11:50 AM

Data from Sangamo BioSciences’ programs to develop ZFN-based therapeutic approaches for the treatment of HIV/AIDS were discussed in four oral presentations at the 18th Conference on Retroviruses and Opportunistic Infections (CROI).

Dr. Carl June presented preliminary data from the ongoing investigator-sponsored phase I trial at the University of Pennsylvania as well as data from Sangamo's phase I dose-escalation trial SB-728-902.  The presentation included new data from subjects on highly active antiretroviral therapy (HAART) who underwent a treatment interruption (TI) for a specified period after treatment with SB-728-T as well as subjects on HAART with undetectable virus but suboptimal CD4+ T-cell counts (200-500 cells/ mm3).

Data on preclinical ZFN-Gene modification studies was presented by Paula Cannon, Ph.D., Associate Professor of Molecular Microbiology & Immunology at the Keck School of Medicine of the University of Southern California (USC). Professor Cannon discussed Sangamo's preclinical program to develop CCR-specific ZFNs to modify the gene in hematopoietic stem cells (HSCs) to provide protection of the entire immune system from HIV infection.

Robert Doms, M.D., Ph.D., Chair, Department of Microbiology, the University of Pennsylvania School of Medicine, presented data regarding Sangamo's ZFN gene-modification program to generate CD4 T-cells that are resistant to so-called "X4-tropic" strains of HIV, strains of HIV that use the CXCR4 co-receptor to infect cells and are characteristic of late-stage HIV infections.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.